UPDATE: Citi Upgrades Zymeworks (ZYME) to Buy, 'Better Risk/Reward Has Emerged'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to UPDATE: Citi Upgrades Zymeworks (ZYME) to Buy, 'Better Risk/Reward Has Emerged'

Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development

January 27, 2021 5:15 PM EST

Active drug with multiple confirmed responses and stable disease observed in several tumor types Differentiated safety profile with the majority of adverse events being grade 1 or 2 Expansion cohorts open and enrolling patients at 2.5 mg/kg once every three weeks Maximum tolerated dose not established, dose escalation continues in parallel

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that the Company has begun enrolling patients into the expansion cohort portion of... More